Bidentate conjugate and method of use thereof

• US 5,196,351 A
• Filed: 06/08/1990
• Issued: 03/23/1993
• Est. Priority Date: 09/30/1987
• Status: Expired due to Fees

• Current Assignee: Beckman Instruments, Inc. (Danaher Corporation)
• Original Assignee: Beckman Instruments, Inc. (Danaher Corporation)
• Inventors: Harris, Paul C., Oh, Chan S.
• Primary Examiner(s): SAUNDERS, DAVID A
• Application Number:
  US07/536,058
• Time in Patent Office: 1,019 Days
• Field of Search: 436/501, 436/517, 436/518, 436/536, 436/543, 436/815, 436/816, 436/817, 436/819, 436/822, 436/805, 530/807
• US Class Current: 436/501
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/532 Production of labelled immunochemicals
• CPC Class Codes: G01N 33/539 involving precipitating reagent , e.g. ammonium sulfate
• CPC Class Codes: G01N 33/54313 the carrier being characterised by its particulate form
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
• CPC Class Codes: Y10S 436/805 Optical property
• CPC Class Codes: Y10S 436/815 Test for named compound or class of compounds
• CPC Class Codes: Y10S 436/816 Alkaloids, amphetamines, and barbiturates
• CPC Class Codes: Y10S 436/817 Steroids or hormones
• CPC Class Codes: Y10S 436/819 Multifunctional antigen or antibody
• CPC Class Codes: Y10S 436/822 Identified hapten

Abstract

A novel bidentate conjugate has two different chemical moieties, or bidentate members, attached through an adequate spacer moiety. Each bidentate member acts as a small molecule ligand and is capable of specifically binding to a different macromolecular substance. The bidentate members are relatively small molecules, usually less than about 7,000 Daltons in size. The spacer moiety is selected so that both bidentate members can simultaneously bind to their respective specific binding partners. Where the specific binding partners are multivalent, large complexes can be formed. The formation of these complexes can be inhibited by the presence of an unconjugated monovalent bidentate member, such as free analyte from a test sample. The bidentate is of particular use in turbidimetric or nephelometric inhibition immunoassay procedures.

Claims

1. An assay for determining the presence of an analyte of interest in a test sample comprising the steps of:

(A) forming a reaction mixture by contacting a test sample with;

(i) at least one bidentate conjugate soluble in the test sample, the conjugate comprising a first bidentate member, a second bidentate member, and a spacer moiety intermediate the first and second bidentate members, wherein;

(a) said first bidentate member and second bidentate member are different small molecule ligands,

(b) said first bidentate member is selected from the group consisting of entities identical to the analyte of interest and entities analogous to to the analyte of interest wherein said analogous entity has the same or substantially the same binding affinity for a binding partner to said analyte of interest,

(c) each of said first and second bidentate members is capable of specifically binding to first and second soluble, non-labeled, multivalent macromolecular binding partners, respectively, and

(d) said spacer moiety is of sufficient length to avoid steric hindrance effects whereby the binding of the first bidentate member to a first binding partner does not prevent the binding of a second bidendate member to a second binding partner;

(ii) at least one soluble, non-labeled, multivalent macromolecular binding partner for said analyte of interest; and

(iii) at least one soluble, non-labeled, multivalent macromolecular binding partner for said second bidentate member;

(B) incubating the reaction mixture for a period of time sufficient to allow formation of at least one complex, said complex comprising at least two different bidentate conjugates bound to the same soluble, non-labeled, multivalent macromolecular binding partner; and

(C) detecting any complexes generated in step (B) by a method utilizing light absorption or light scattering.

2. The assay of claim 1 wherein said first bidentate member is selected from the group consisting of haptens, hormones, polypeptides, and vitamins.

3. The assay of claim 1 wherein said first bidentate member is a hapten with a molecular weight between about 100 and about 1500 Daltons.

4. The assay of claim 1 wherein said first bidentate member is selected from the group consisting of theophylline, digoxin, disopyramide, lidocaine, procainamide, propranolol, quinidine, amykamycin, chloramphenicol, gentamicin, kanamycin, netilmycin, tobramycin, tricyclic antidepressants, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, acetaminophen, acetysalicylic acid, methotrexate, drugs of abuse, metabolites of drugs of abuse, DNP, 1-substituted-4-hydroxy-2 nitrobenzene, and 4-substituted-2-nitro-trialkylanilinium salts.

5. The assay of claim 1 wherein said second bidentate member is biotin.

6. The assay of claim 5 wherein said second binding partner is avidin.

7. The assay of claim 1 wherein said spacer moiety is at least about 23.5Å

in length.

8. The assay of claim 1 wherein said first bidentate member is theophylline, said first binding partner is anti-theophylline antibody, said second bidentate member is biotin and said second binding partner is avidin.

9. The assay of claim 1 wherein at least one of the first or the second binding partners is divalent.

10. The assay of claim 9 wherein said first bidentate member is a hapten with a molecular weight of between about 100 and about 1500 Daltons and said first binding partner is an antibody specific for said hapten.

11. The assay of claim 10 wherein said second bidentate member is biotin and said second binding partner is avidin.

12. The assay of claim 1 wherein both of the first and second binding partners are divalent.